Search

Displaying results 4761 - 4770 of 10000 in total
  1. Drug

    Zilovertamab vedotin

    go.drugbank.com/drugs/DB18457
    Investigational

    Zilovertamab vedotin is an Antibody-drug conjugate (ADC) comprising an anti-ROR1 monoclonal antibody (UC-961), a proteolytically cleavable maleimidocaproyl-valine-citrulline-para-aminobenzoate linker ( … mc-vc-PAB), and a monomethyl auristatin E (MMAE) cytotoxin.

  2. Drug

    Eldelumab

    go.drugbank.com/drugs/DB06116
    Investigational

    MDX-1100, a fully human antibody that targets IP10 (also known as CXCL10), a chemokine expressed in association with multiple inflammatory disease indications, such as rheumatoid arthritis, inflammatory

  3. Drug

    AVE9633

    go.drugbank.com/drugs/DB06318
    Investigational

    AVE9633 is an anti-CD33 monoclonal antibody-DM4 conjugate.

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  4. Drug

    Hu-PHEC Liver

    go.drugbank.com/drugs/DB18347
    Experimental

    Hu-PHEC Liver is an adult hemogenic endothelial cells.

  5. Drug

    NN-8828

    go.drugbank.com/drugs/DB18361
    Investigational

    NN-8828 is an anti-interleukin 21 monoclonal antibody.

  6. Drug

    Ethyl pyruvate

    go.drugbank.com/drugs/DB05869
    Investigational

    CTI-01 (ethyl pyruvate) is a novel anti-inflammatory agent for the treatment of critical inflammatory conditions. … CTI-01 shows a potent anti-inflammatory and tissue protection activity in multiple animal models of disease including pancreatitis, ischemia-reperfusion injury, sepsis, renal injury and endotoxemia.

  7. Drug

    Neramexane

    go.drugbank.com/drugs/DB04926
    Investigational

    Neramexane is a low-to-moderate affinity uncompetitive NMDA receptor antagonist.

  8. Drug

    CT103A

    go.drugbank.com/drugs/DB18180
    Investigational

    CT103A is an investigational BCMA-targeted genetically modified autologous T-cell immunotherapy.

  9. Drug

    CT120

    go.drugbank.com/drugs/DB18181
    Investigational

    CT120 is an investigational autologous CD19/22 targeted CAR-T cell immunotherapy.

  10. Drug

    CAM-101

    go.drugbank.com/drugs/DB18414
    Investigational

    CAM-101 is an allogeneic human platelet lysate product depleted of fibrinogen.